Primary amyloidosis – Life with Disease

Go back

Primary amyloidosis, also known as AL amyloidosis, is a rare disorder where abnormal protein fragments build up in organs and tissues throughout the body. These protein deposits, called amyloid, can affect how vital organs function and may lead to serious health complications. Understanding what to expect with this condition can help patients and families prepare for the journey ahead.

Prognosis and Life Expectancy

Learning about life expectancy after a diagnosis of primary amyloidosis can be one of the most difficult conversations for patients and their loved ones. The outlook for each person depends heavily on which organs are affected and how severely the disease has progressed at the time of diagnosis. This is deeply personal information, and every patient’s journey is unique.[1][2]

The heart and kidneys are the organs most commonly damaged by amyloid deposits. When the heart is involved, this becomes the most important factor in determining how long someone might live. Patients with significant heart damage face more serious challenges than those whose hearts are less affected. In fact, heart complications are the leading cause of death in people with AL amyloidosis.[5][6]

Without treatment, the disease can progress rapidly. Historical data showed that widespread amyloidosis could lead to death within two years. However, this grim statistic comes from an era before modern treatments were available. Today, the picture is considerably brighter for many patients.[2]

Early diagnosis and prompt treatment are absolutely critical for improving survival. Patients who receive care at specialized amyloid centers and respond well to treatment can often achieve remission. In experienced centers, many patients who survive the first six months after diagnosis begin to recover and can live normal or nearly normal lives for years, sometimes a decade or longer.[3][14]

⚠️ Important
The degree of heart involvement is the single most important factor affecting prognosis in AL amyloidosis. Patients with advanced heart damage at diagnosis face more serious challenges, but even those with significant heart involvement can benefit greatly from treatment at experienced amyloid centers. Early detection and treatment can prevent further organ damage and improve outcomes.

The disease affects approximately 9 to 14 people per million each year in the United States, making it relatively rare. Most people are diagnosed after age 50, with the average age at diagnosis being around 64 years. The condition affects slightly more men than women.[7][9]

Natural Progression Without Treatment

When primary amyloidosis goes untreated, abnormal light chain proteins continue to accumulate in tissues and organs, causing progressive damage. The disease does not resolve on its own, and the buildup of amyloid deposits only worsens over time. This relentless accumulation interferes with normal organ function in increasingly harmful ways.[2]

The abnormal proteins come from plasma cells in the bone marrow. In AL amyloidosis, these cells produce excessive amounts of defective light chain proteins. Unlike normal proteins that are properly formed and used by the body, these abnormal light chains misfold and clump together. They form rigid, insoluble fibers called amyloid fibrils that resist the body’s natural breakdown processes. These fibrils then deposit in various organs, surrounding and suffocating healthy tissue.[3][5]

As amyloid continues to deposit in the heart, the heart walls become thicker and stiffer. This makes it increasingly difficult for the heart to relax between beats and to pump blood effectively. Over time, this leads to congestive heart failure, a condition where the heart cannot pump enough blood to meet the body’s needs. The heart’s electrical system can also be disrupted, causing dangerous irregular heartbeats that may be too fast or too slow. Some patients develop low blood pressure, especially when standing up, which can cause dizziness and fainting.[2][5]

In the kidneys, progressive amyloid deposits damage the filtering units that clean the blood. This leads to protein leaking into the urine, a condition that can cause the body to swell as fluid accumulates in the legs, ankles, and other areas. Eventually, kidney function declines to the point of kidney failure, which may require dialysis to sustain life.[2][6]

Nerve damage worsens gradually when amyloid deposits in the nervous system. Patients experience increasing numbness, tingling, pain, or weakness in their hands and feet. The autonomic nervous system, which controls automatic body functions, can also be affected. This leads to problems regulating blood pressure, difficulties with digestion causing severe diarrhea or constipation, and problems with bladder control.[5][6]

Other organs suffer as well. The liver and spleen may enlarge, though liver function usually remains relatively preserved until late in the disease. The digestive tract can be affected, causing difficulty swallowing, ongoing nausea, and problems absorbing nutrients from food, leading to significant weight loss. The tongue may become unusually large, a distinctive feature called macroglossia.[1][5]

Possible Complications

Primary amyloidosis can lead to a wide range of complications, some of which develop unexpectedly and can be quite serious. These complications arise from the buildup of amyloid in various body systems and can significantly affect quality of life and survival.[2]

Heart-related complications are among the most serious and common. Between 70 and 80 percent of people with AL amyloidosis have heart involvement. The heart may develop cardiomyopathy, a disease of the heart muscle that makes it difficult to pump blood. This can progress to heart failure, where the heart simply cannot keep up with the body’s demands for oxygen and nutrients. Abnormal heart rhythms, including dangerously slow heartbeats or rapid, chaotic rhythms, may develop. Some patients require pacemakers or implantable defibrillators to regulate their heart rhythm. Blood clots can form in the heart’s chambers when they cannot contract properly, raising the risk of stroke.[5][6]

Kidney complications affect 60 to 70 percent of patients. The most common problem is nephrotic syndrome, a collection of symptoms that includes large amounts of protein in the urine, low protein levels in the blood, high cholesterol, and severe swelling throughout the body. This swelling, called edema, can be uncomfortable and limiting. Some patients progress to complete kidney failure, requiring regular dialysis treatments to artificially filter their blood. In severe cases, a kidney transplant may be considered.[2][4]

Neurological complications can be disabling. Peripheral neuropathy, which affects the nerves in the hands and feet, causes ongoing pain, numbness, and tingling sensations. These symptoms can make it difficult to perform everyday tasks like buttoning clothes or walking safely. Some patients develop carpal tunnel syndrome, where nerve compression in the wrist causes pain and weakness in the hand. Damage to the autonomic nervous system causes orthostatic hypotension, a dangerous drop in blood pressure when standing that can lead to falls and injuries.[2][5]

Bleeding problems can occur because amyloid deposits in blood vessels make them fragile. Small blood vessels in the skin may leak, causing bruising even from minor bumps. A characteristic pattern of purple-colored bruising around the eyes, sometimes called “raccoon eyes,” is particularly common. Some patients bruise easily all over their body. In more severe cases, bleeding can occur in the digestive tract.[1][6]

Digestive complications range from uncomfortable to debilitating. Patients may experience severe diarrhea or constipation, sometimes alternating between the two. Difficulties swallowing can make eating unpleasant and may lead to malnutrition. Poor absorption of nutrients from food contributes to unintentional weight loss and weakness. Nausea and loss of appetite are common, further compounding nutritional problems.[1][2]

Less common but notable complications include liver enlargement and dysfunction, though complete liver failure is rare. The spleen may not function properly, increasing the risk of infections. Some patients develop problems with their endocrine glands, including the adrenal and thyroid glands. Lung involvement can cause shortness of breath. Skin changes may include thickening, unusual growths, or color changes.[2][5]

Impact on Daily Life

Living with primary amyloidosis affects nearly every aspect of daily life, from physical capabilities to emotional wellbeing, social relationships, work life, and personal hobbies. The disease brings both visible and invisible challenges that require significant adjustments.[15]

Physical limitations can be profound. Severe fatigue is one of the most common and debilitating symptoms. This is not ordinary tiredness that improves with rest—it is an overwhelming exhaustion that can make even simple tasks feel impossible. Getting dressed, preparing meals, or taking a shower may require rest breaks. Many patients find they need to sleep more than before or take frequent naps during the day.[1][4]

Shortness of breath limits physical activity. Walking up stairs, carrying groceries, or maintaining a conversation while moving may become difficult or impossible. This breathlessness can also interfere with sleep, especially when lying flat. Some patients need to sleep propped up on pillows or in a reclining chair.[1]

Swelling in the legs and ankles makes shoes uncomfortable and walking difficult. The extra fluid weight can be significant, making movement more tiring. Some patients need to elevate their legs frequently or adjust their shoe size. Maintaining balance becomes harder, increasing the risk of falls.[4][15]

Numbness and pain in the hands and feet create practical challenges. Difficulty gripping objects may make it hard to open jars, use utensils, or write. Numbness in the feet increases fall risk because patients cannot feel the ground properly beneath them. Some people accidentally burn themselves because they cannot sense hot or cold temperatures normally.[17][15]

Work life often requires major adjustments or may become impossible. The unpredictable nature of symptoms makes it hard to maintain regular work schedules. Frequent medical appointments for tests and treatments require time off. Physical jobs may become too demanding. Even desk jobs can be challenging when fatigue, pain, or medication side effects interfere with concentration. Some patients need to reduce their hours, switch to less demanding roles, or stop working entirely. This loss can be emotionally difficult and financially stressful.[16]

Social activities and hobbies often need to be modified or abandoned. Fatigue and physical limitations may prevent participation in activities that once brought joy. Travel becomes complicated due to medical needs and unpredictable symptoms. Social gatherings can be exhausting, and patients may decline invitations to conserve energy. This can lead to feelings of isolation and missing out on life.[15][20]

Emotional wellbeing suffers under the weight of chronic illness. Anxiety about the future is common, especially given the serious nature of the disease. Depression can develop as patients grieve the loss of their former health and capabilities. Frustration with physical limitations and dependence on others can be overwhelming. The uncertainty of not knowing how the disease will progress adds ongoing stress.[15]

Relationships with family and friends change. Patients may need help with tasks they once did independently, from household chores to personal care. This can create feelings of guilt and burden. Partners and family members take on caregiver roles, which can strain relationships. Open communication becomes more important than ever.[15][16]

⚠️ Important
Managing daily life with AL amyloidosis requires practical adjustments. Keep detailed records of symptoms and side effects to share with your healthcare team. Consider using mobility aids like walking sticks if needed. Pace yourself by prioritizing important activities and resting between tasks. Stay hydrated by drinking 2-3 liters of water daily unless your doctor advises otherwise. Maintain a low-salt diet and eat nutritious foods to support your overall health.

Financial concerns add another layer of stress. Medical bills can mount quickly. Loss of income from reduced work capacity creates hardship for many families. Some patients qualify for government disability benefits, financial assistance programs, or support for caregivers, though these vary by country and can be complicated to access.[16]

Coping strategies can help maintain quality of life despite limitations. Connecting with other patients through support groups provides understanding and practical advice from people who truly know what you are going through. Maintaining communication with your healthcare team ensures symptoms are managed as effectively as possible. Setting realistic expectations and celebrating small victories helps maintain a positive outlook. Asking for and accepting help from others is not weakness—it is wisdom.[15][21]

Support for Family Members

When someone is diagnosed with primary amyloidosis, their family members become important partners in the journey ahead. Understanding what families need to know about clinical trials and how they can support their loved one is essential for navigating this challenging time together.[18]

Clinical trials offer hope for patients with AL amyloidosis. These research studies test new treatments, drug combinations, or approaches that are not yet widely available. Because AL amyloidosis is rare and research is ongoing, clinical trials may provide access to cutting-edge therapies that could be more effective than standard treatments. All patients with AL amyloidosis should be considered for enrollment in clinical trials when appropriate options are available.[4][13]

Understanding clinical trials helps families support their loved one in making informed decisions. Clinical trials have different phases. Some test new drugs that have never been used in humans before, while others compare new treatments to existing standard care. Some focus on people who have just been diagnosed, while others are for patients whose disease has come back after previous treatment. Each trial has specific eligibility criteria based on factors like age, disease stage, organ involvement, and previous treatments.[12]

Family members can help their loved one find clinical trials in several ways. Specialized amyloid treatment centers often have active research programs and can discuss trial options during appointments. National organizations dedicated to amyloidosis maintain lists of current trials and can provide information about what is available. Online clinical trial registries allow families to search for studies by location and disease type. Asking the patient’s healthcare team directly about trial opportunities is always appropriate.[4][18]

Once a potential trial is identified, families can assist with the preparation and decision-making process. Attending appointments together ensures that two people hear the information, as it can be overwhelming and easy to forget details. Taking notes or recording conversations (with permission) helps review information later. Preparing questions beforehand ensures important concerns are addressed. Questions might include: What is the purpose of this trial? What are the potential benefits and risks? How does this compare to standard treatment? What will participation involve in terms of time commitment and travel? What happens if the treatment does not work or causes serious side effects?[18]

Practical support for clinical trial participation is valuable. Many trials require frequent visits to the research center, sometimes more often than standard care. Family members can help with transportation, especially when the patient is too tired or unwell to drive. Keeping track of appointment schedules, medication schedules, and symptom diaries can be overwhelming for the patient—sharing this burden helps. Organizing medical records and test results needed for trial enrollment saves time and reduces stress.[18]

Families should understand that not all clinical trials are appropriate for every patient. Eligibility criteria may exclude some people. The patient’s overall health, particularly the degree of organ damage, affects whether they can safely participate. Some trials involve travel to distant specialized centers, which may not be feasible for everyone. The decision to participate is deeply personal and should be made without pressure.[12]

Beyond clinical trials, family members provide crucial emotional and practical support. Simply being present and listening without judgment matters more than having solutions. Helping with daily tasks like cooking, cleaning, shopping, or managing medications eases the burden on the patient. Attending medical appointments provides another set of ears to hear complex information and another voice to ask questions. Advocating for the patient’s needs with healthcare providers when the patient is too tired or overwhelmed to do so themselves is invaluable.[15][16]

Learning about the disease helps family members understand what their loved one is experiencing. Reading reliable information from established medical centers and patient organizations provides accurate knowledge. Joining support groups for caregivers connects families with others in similar situations who can offer practical advice and emotional understanding. Some organizations offer specific programs for family members and caregivers.[4][18]

Taking care of themselves is essential for family caregivers. The stress of caring for someone with a serious illness can lead to burnout, affecting physical and mental health. Caregivers should maintain their own medical appointments, eat well, exercise when possible, and get adequate rest. Accepting help from others and taking breaks is not selfish—it is necessary for sustainable caregiving. Some regions offer respite care services or caregiver support allowances.[16]

Communication within the family is vital. Discussing concerns, fears, and hopes openly strengthens relationships during difficult times. Including the patient in decisions about their care respects their autonomy and preferences. Talking about practical matters, including financial concerns and future care needs, helps everyone prepare and reduces uncertainty.[16]

Most importantly, families should remember that seeking information and support is a sign of strength, not weakness. The journey with AL amyloidosis is challenging, but no one needs to face it alone. Healthcare teams, patient organizations, and other families who have walked this path are ready to help.

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Daratumumab – A monoclonal antibody used in combination with cyclophosphamide, bortezomib, and dexamethasone as the first FDA-approved treatment specifically for newly diagnosed AL amyloidosis
  • Cyclophosphamide – A chemotherapy drug used to reduce abnormal plasma cells
  • Melphalan – A chemotherapy drug used in high doses as part of stem cell transplant procedures or in combination therapy
  • Bortezomib – A proteasome inhibitor that blocks enzyme activity in cells, used to treat multiple myeloma and AL amyloidosis
  • Dexamethasone – A steroid medication used in combination regimens
  • Prednisone – A steroid medication used to treat AL amyloidosis
  • Lenalidomide – An immunomodulatory drug used in treatment regimens
  • Pomalidomide – An immunomodulatory drug used in treatment protocols
  • Ixazomib – A proteasome inhibitor used in treatment combinations

Ongoing Clinical Trials on Primary amyloidosis

  • Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

    Recruiting

    3 1 1 1
    France
  • Study of Teclistamab for Patients with Previously Treated AL Amyloidosis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy The Netherlands
  • Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Belgium Denmark France Germany Greece Hungary +5
  • Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

    Not recruiting

    3 1 1
    Investigated diseases:
    Austria Belgium Czechia Denmark France Germany +8

References

https://www.mayoclinic.org/diseases-conditions/amyloidosis/symptoms-causes/syc-20353178

https://medlineplus.gov/ency/article/000533.htm

https://stanfordhealthcare.org/medical-conditions/blood-heart-circulation/amyloidosis/types/al-primary-amyloidosis.html

https://arci.org/about-amyloidosis/al-amyloidosis/

https://en.wikipedia.org/wiki/AL_amyloidosis

https://emedicine.medscape.com/article/1093258-overview

https://pmc.ncbi.nlm.nih.gov/articles/PMC8932379/

https://www.mayoclinic.org/diseases-conditions/amyloidosis/diagnosis-treatment/drc-20353183

https://my.clevelandclinic.org/health/diseases/15718-amyloidosis-al-amyloid-light-chain

https://www.fredhutch.org/en/diseases/amyloidosis/treatment.html

https://arci.org/about-amyloidosis/al-amyloidosis/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11991823/

https://emedicine.medscape.com/article/1093258-treatment

https://www.cedars-sinai.org/health-library/diseases-and-conditions/a/al-amyloidosis.html

https://www.emea.jnjwithme.com/en/blood-cancer/amyloidosis/living-with-al-amyloidosis

https://www.mpeurope.org/what-we-do/educational-resources/qas/living-with-al-amyloidosis/

https://my.clevelandclinic.org/health/diseases/15718-amyloidosis-al-amyloid-light-chain

https://arci.org/patients-and-caregivers/new-to-amyloidosis/

https://www.mayoclinic.org/diseases-conditions/amyloidosis/diagnosis-treatment/drc-20353183

http://www.cardiosmart.org/topics/cardiac-amyloidosis/living-with-cardiac-amyloidosis

https://www.mpeurope.org/myeloma-and-al-amyloidosis/about-al-amyloidosis/al-amyloidosis-caring-for-yourself/

https://stanfordhealthcare.org/medical-conditions/blood-heart-circulation/amyloidosis.html

FAQ

Is AL amyloidosis a type of cancer?

AL amyloidosis is not cancer, but it is closely related to cancer. It occurs when plasma cells in the bone marrow produce abnormal proteins. About 10-15% of patients with AL amyloidosis also have multiple myeloma, which is a cancer of plasma cells. While AL amyloidosis shares some characteristics and treatments with multiple myeloma, the main problem is the buildup of abnormal proteins rather than the rapid growth of abnormal cells.

Can AL amyloidosis be inherited or passed to children?

No, AL amyloidosis is not considered hereditary and cannot be passed from parents to children. It develops when plasma cells spontaneously begin producing abnormal light chain proteins. This is different from some other types of amyloidosis, such as hereditary ATTR amyloidosis, which does run in families.

Why is AL amyloidosis often diagnosed late?

AL amyloidosis is frequently diagnosed late because its symptoms mimic many more common conditions. Fatigue, shortness of breath, and swelling can be attributed to aging or other diseases. Around 70% of patients do not receive a diagnosis for over a year after symptoms begin, and one-third visit more than five doctors before the correct diagnosis is made. The disease is also rare, so many physicians have limited experience recognizing it.

Can AL amyloidosis go into remission?

Yes, with modern treatments, AL amyloidosis can go into remission. The goal of treatment is to achieve a complete or very good partial response, where the abnormal protein levels drop significantly or become undetectable. When remission is achieved, it can last for years—sometimes a decade or longer. Early diagnosis and treatment at specialized centers improve the chances of achieving and maintaining remission.

What is the difference between AL amyloidosis and other types of amyloidosis?

Different types of amyloidosis are caused by different proteins. AL amyloidosis is caused by abnormal light chain proteins from plasma cells. ATTR amyloidosis is caused by a different protein called transthyretin and can be either inherited or age-related. AA amyloidosis is caused by serum amyloid A protein and occurs with chronic inflammatory diseases. Each type has different causes, treatments, and outlooks, which is why identifying the specific type is crucial.

🎯 Key takeaways

  • The degree of heart involvement is the single most important factor determining life expectancy in AL amyloidosis patients
  • Modern treatments can achieve remissions lasting a decade or longer, dramatically improving outcomes compared to the past
  • Most patients see more than five doctors before receiving the correct diagnosis because symptoms mimic common conditions
  • AL amyloidosis affects only 9-14 people per million annually in the US, making it exceptionally rare
  • Daratumumab combination therapy is the first and only FDA-approved treatment specifically for newly diagnosed AL amyloidosis
  • Between 70-80% of patients have heart involvement and 60-70% have kidney involvement at diagnosis
  • Clinical trials offer access to cutting-edge therapies that may be more effective than standard treatments
  • Patients who survive the first six months after diagnosis often begin to recover and can live relatively normal lives for years